Ardelyx Reports Strong Preliminary Q4 and Full-Year 2025 Product Sales for IBSRELA and XPHOZAH

summarizeSummary

Ardelyx announced robust preliminary unaudited net product sales for IBSRELA and XPHOZAH for Q4 and full-year 2025, alongside a healthy cash balance, indicating strong commercial performance.

check_boxKey Events

• Strong Preliminary Product Sales

  Reported unaudited U.S. net product sales of approximately $87 million for IBSRELA and $28 million for XPHOZAH in Q4 2025.

• Robust Full-Year Performance

  Full-year 2025 unaudited U.S. net product sales reached approximately $274 million for IBSRELA and $104 million for XPHOZAH.

• Healthy Cash Position

  The company ended 2025 with approximately $265 million in unaudited cash, cash equivalents, and short-term investments.

• Preliminary Data Caveat

  All reported financial figures are preliminary, unaudited, and subject to potential material adjustments in the final audited financial statements.

auto_awesomeAnalysis

This 8-K filing provides an early, positive look at Ardelyx's commercial execution for its key products, IBSRELA and XPHOZAH. The preliminary sales figures, totaling approximately $115 million for Q4 2025 and $378 million for the full year, demonstrate significant market traction. The reported cash, cash equivalents, and short-term investments of $265 million as of year-end 2025 also indicate a strong financial position, providing a substantial runway for operations. While these figures are unaudited and subject to adjustment, they offer a compelling signal of the company's operational strength and potential for continued growth. Investors should monitor the upcoming audited financial statements for confirmation.